Cost-Effectiveness of Tislelizumab Versus Docetaxel for Previously Treated Advanced Non-Small-Cell Lung Cancer in China.

Front Pharmacol · 2022 · PMC9124929 · PMID 35614942

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

When using the utility values of 0.673 and 0.473 for PFS and PD, respectively ( Nafees et al., 2008 ), the ICER presented some extent of an increasing trend but still not exceeding the CET we set.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.